Targeting AXL could block the activation of the Gas6/AXL pathway, inhibit the proliferation of AML cells, and overcome the resistance of FLT3-ITD + AML cells to FLT3 inhibitors. This evidence concerns the gene GAS6 and acute myeloid leukemia.